International Experts Address GLP-1 Medication Use Around Pregnancy
Original Article: https://www.medscape.com/viewarticle/international-consensus-addresses-glp-1-ra-use-pregnancy-2026a10012h2
Why Guidance Is Needed
GLP-1 receptor agonists, including semaglutide and liraglutide, are widely used to manage type 2 diabetes and obesity. However, evidence about their safety before, during, and after pregnancy remains limited. An international expert group developed recommendations for women with type 1 diabetes, type 2 diabetes, or gestational diabetes who may use these medications around pregnancy.
What the Evidence Shows
The experts reviewed published research involving nearly 50,000 women. The analysis found no clear increase in congenital abnormalities when GLP-1 medications were stopped during the first trimester. However, early pregnancy loss, including miscarriage or termination, was more common among women exposed to these medications. The researchers cautioned that this finding was difficult to interpret because some studies combined miscarriage and pregnancy termination into a single outcome. Overall, the certainty of the evidence was rated very low, highlighting the need for better research.
Recommendations for Pregnancy Planning
GLP-1 medications are not currently recommended for routine use during pregnancy because their safety has not been established. Women planning pregnancy should work with their healthcare professionals to determine when to stop treatment and how to manage blood sugar and weight afterward. For people with diabetes, this may involve transitioning to treatments suitable for pregnancy, such as insulin, while maintaining appropriate glucose control.
The Takeaway
International experts have developed guidance for managing GLP-1 medications before, during, and after pregnancy, but important safety questions remain. Women taking these medications who are planning pregnancy or become pregnant should consult their healthcare team about treatment changes. Larger, higher-quality studies are needed to clarify the effects of GLP-1 medications on pregnancy outcomes.

